Genotypic antiretroviral drug resistance testing at low viral loads in the UK

HIV Med. 2008 Oct;9(8):673-6. doi: 10.1111/j.1468-1293.2008.00607.x. Epub 2008 Jun 28.

Abstract

Background: Antiretroviral drug resistance testing is recommended in HIV-1 infected patients failing therapy in order to inform treatment selection. Although guidelines and test manufacturers recommend a viral load of at least 500-1000 HIV-1 RNA copies/mL for genotypic resistance testing to be performed, prompt management of virological failure could benefit from testing at lower viral load levels.

Methods: Laboratories undertaking genotypic resistance testing were asked to provide figures for the number of resistance tests undertaken at viral loads <2000 copies/mL, the success rates of such tests and the extent of resistance detected, all stratified for viral load levels.

Results: Of the replies received, most laboratories were attempting resistance testing at viral loads below the recommended guidelines, with variable success and outcomes.

Conclusions: This audit of current practice in the UK for undertaking genotypic resistance tests at viral loads <1000 copies/mL highlights the widespread use of such testing outside the British HIV Association guidelines.

MeSH terms

  • Anti-Retroviral Agents*
  • Drug Resistance, Multiple, Viral / genetics*
  • Genotype
  • Guideline Adherence
  • HIV Infections / virology*
  • HIV-1 / genetics*
  • Humans
  • Laboratories
  • Medical Audit*
  • RNA, Viral / genetics*
  • Sensitivity and Specificity
  • Viral Load
  • Virology

Substances

  • Anti-Retroviral Agents
  • RNA, Viral